evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,703 questions · 15,007 findings · 1,416 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Tranexamic acid vs placebo

Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery

It is very uncertain whether summary of findings: Tranexamic acid changes risk of reoperation or repeat procedure for bleeding within 7 days compared with placebo (very low certainty).

1 finding from 1 review

Tranexamic acid vs placebo

Risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) · people aged 18 and over undergoing vascular surgery

Summary of findings: Tranexamic acid showed no clear difference in risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) compared with placebo (low certainty).

1 finding from 1 review

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

All‐cause infant mortality at longest · HIV‐positive pregnant women co‐infected with hepatitis B virus

It is very uncertain whether tenofovir‐based antiviral combination regimens changes all‐cause infant mortality at longest compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).

1 finding from 1 review

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

Proportion of infants with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus

It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of infants with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).

1 finding from 1 review

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

Proportion of infants with HBV mother‐to‐child transmission · HIV‐positive pregnant women co‐infected with hepatitis B virus
1 finding from 1 review

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

Proportion of mothers with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus

It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of mothers with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

It is very uncertain whether summary of findings table ‐ Oral classical immunosuppressants… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in short‐term hair regrowth ≥ 75% compared with placebo (low certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Oral small molecule inhibitors… leads to higher short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (high certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Incidence of serious adverse events · adults with alopecia areata

Summary of findings table ‐ Oral small molecule inhibitors… showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Oral small molecule inhibitors… leads to higher long‐term hair regrowth ≥ 75% (greater than 26 weeks of compared with placebo (high certainty).

1 finding from 1 review